Aiymkul Ashimkhanova

Aiymkul Ashimkhanova

Auto-generated profile, based on publicly available information

Aiymkul Ashimkhanova

School of Medicine, Nazarbayev University, Nur Sultan (Astana), Kazakhstan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Antiviral Research
Verified
Journal Article
Closed access
AAAigerim Abdrakhman
Aigerim Abdrakhman
AAAiymkul Ashimkhanova
Aiymkul Ashimkhanova
WAWassim Almawi
Wassim Almawi

20 July 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
AAAiymkul Ashimkhanova
Aiymkul Ashimkhanova
DODamesh Orazbayeva
Damesh Orazbayeva
AAAibar Agynbay
Aibar Agynbay
MZMarzhan Zhanasbayeva
Marzhan Zhanasbayeva
KKKulpash Kaliaskarova
Kulpash Kaliaskarova
RKRaima Kapiyeva
Raima Kapiyeva

1 March 2023 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
AGA Gainutdin
A Gainutdin
NANazugum Ashimova
Nazugum Ashimova
ANAlexander V Nersesov
Alexander V Nersesov
AIAlpamys Issanov
Alpamys Issanov
TTT Tajibayev
T Tajibayev
ASAlmaty Jsc “A.N. Syzganov National Scientific Center Of Surgery”
Almaty Jsc “A.N. Syzganov National Scientific Center Of Surgery”
Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is one of the most significant diseases that is predominantly verified in women. The prevalence of PBC is 1.9-40.2 per 100,000 population. Antimitochondrial antibodies (AMA) are of major importance for the diagnosis of primary biliary cirrhosis (PBC), and it has also been suggested that they may be involved in the pathogenesis of the disease. Objective: The aim of this study was to characterize the clinical, biochemical parameters and response to UDCA (Paris I criteria) PBC patients depending on AMA status in the Republic of Kazakhstan. Material and methods. The study was conducted on the basis of the Research Institute of Cardiology and Internal Diseases from 2014 to 2019. A total of 212 patients with primary biliary cholangitis were recorded. Results. Among 212 patients, 171 (80.7%) were AMA-positive and 41(19,3%) - AMA-negative. Vast majority of patients in both groups were Asian (179; 84.4%) and female (206; 97.2%). Severe disease (F3/4) was revealed in 108 (63.2%) AMA-positive and in 18 (43.9 %) AMA-negative patients (p>0.05). AMA-positive and AMA-negative PBC were associated with autoimmune hepatitis in 88 (51.5%) and 10 (24.4%) cases (p0.05). Response to ursodeoxycholic acid (UDCA) treatment according to Paris I criteria was noted in 24 out of 81 (29.6%) AMA-positive and in 9 out of 22 (40.9%) AMA-negative patients (p>0.05). Conclusion. In patients with AMA-positive PBC compared with AMA-negative, there is a statistically significant high value of autoimmune hepatitis and autoimmune thyroiditis. Whereas, response to UDCA treatment according to Paris I criteria is higher in AMA-negative PBC.